Gossamer Bio, Inc.
GOSS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728117
No open-market purchases or sales by Gossamer Bio, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $60.8M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Gossamer Bio, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 94 | 1 | 100 | +7 |
| Shares | 182.9M | 2.81M | 174.9M | −5.16M (−2.9%) |
| Value | $164.7M | $2.53M | $172.6M | +$10.4M (+6.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Gossamer Bio, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Siren, L.L.C. | 13,281,610 | $13.1M | 0.66% |
| BlackRock, Inc. | 2,805,642 | $2.77M | 0.00% |
| Diametric Capital, LP | 287,259 | $283.4K | 0.14% |
| State of Wyoming | 242,649 | $239.3K | 0.03% |
| Squarepoint Ops LLC | 146,957 | $145.0K | 0.00% |
| Aster Capital Management (DIFC) Ltd | 134,563 | $132.7K | 0.03% |
| Prelude Capital Management, LLC | 104,612 | $103.2K | 0.01% |
| Gsa Capital Partners LLP | 67,546 | $67.0K | 0.01% |
| Mackenzie Financial Corp | 50,050 | $49.4K | 0.00% |
| Prudential Financial Inc | 47,050 | $46.4K | 0.00% |
| US Bancorp | 39,655 | $39.1K | 0.00% |
| HB Wealth Management, LLC | 27,500 | $27.1K | 0.00% |
| Stephenson National Bank & Trust | 20,000 | $19.7K | 0.01% |
| Group One Trading, L.P. | 11,064 | $10.9K | 0.00% |
| Lazard Asset Management LLC | 1,328 | $1.00K | 0.00% |
| CIBC Private Wealth Group, LLC | 1,000 | $986 | 0.00% |
| Northwestern Mutual Wealth Management Co | 261 | $257 | 0.00% |
Sold out (10)
Institutions that held Gossamer Bio, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 13,308,968 | $12.0M |
| Sphera Funds Management Ltd. | 222,134 | $200.1K |
| Jane Street Group, LLC | 93,354 | $84.1K |
| LMR Partners LLP | 58,445 | $52.7K |
| Nomura Holdings Inc | 40,000 | $36.0K |
| Graham Capital Management, L.P. | 10,484 | $9.45K |
| Texas Yale Capital Corp. | 10,000 | $9.01K |
| Cape Investment Advisory, Inc. | 7,000 | $6.31K |
| Rhumbline Advisers | 2,834 | $2.55K |
| Global Retirement Partners, LLC | 300 | $270 |
Not filed for Q3 2024 yet (1)
Institutions that held Gossamer Bio, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,811,507 | $2.53M |